Literature DB >> 18432877

Cloning, expression, and modification of antibody V regions.

Sherie L Morrison1.   

Abstract

Cloned variable (V) regions of antibodies can be expressed joined to any constant (C) region, from either the same or a different species. The resulting antibodies will have the desired associated effector functions. Chimeric antibodies obtained by joining murine V regions to human C regions should have decreased immunogenicity in humans. The process of complementarity determining region (CDR) grafting, in which the CDRs from an antibody of one species are transferred to the framework regions of another species, constitutes a further modification of this approach. The protocols presented in this unit are designed to permit PCR-based cloning of heavy and light chain V regions. This is an advanced molecular biology protocol and should be employed only by investigators who are sufficiently skilled and experienced.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 18432877     DOI: 10.1002/0471142735.im0212s47

Source DB:  PubMed          Journal:  Curr Protoc Immunol        ISSN: 1934-3671


  4 in total

1.  Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.

Authors:  Uranan Tumkosit; Uamporn Siripanyaphinyo; Naokazu Takeda; Motonori Tsuji; Yusuke Maeda; Kriangsak Ruchusatsawat; Tatsuo Shioda; Hiroto Mizushima; Prukswan Chetanachan; Pattara Wongjaroen; Yoshiharu Matsuura; Masashi Tatsumi; Atsushi Tanaka
Journal:  J Virol       Date:  2020-09-15       Impact factor: 5.103

2.  A single glycan on IgE is indispensable for initiation of anaphylaxis.

Authors:  Kai-Ting C Shade; Barbara Platzer; Nathaniel Washburn; Vinidhra Mani; Yannic C Bartsch; Michelle Conroy; Jose D Pagan; Carlos Bosques; Thorsten R Mempel; Edda Fiebiger; Robert M Anthony
Journal:  J Exp Med       Date:  2015-03-30       Impact factor: 14.307

3.  Nanocell targeting using engineered bispecific antibodies.

Authors:  Karin Taylor; Christopher B Howard; Martina L Jones; Ilya Sedliarou; Jennifer MacDiarmid; Himanshu Brahmbhatt; Trent P Munro; Stephen M Mahler
Journal:  MAbs       Date:  2015       Impact factor: 5.857

4.  Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and InVitro Efficacy Analysis.

Authors:  Swetha Tati; John C Fisk; Julia Abdullah; Loukia Karacosta; Taylor Chrisikos; Padraic Philbin; Susan Morey; Diala Ghazal; Fatma Zazala; Joseph Jessee; Sally Quataert; Stephen Koury; David Moreno; Jing Ying Eng; Vladislav V Glinsky; Olga V Glinskii; Muctarr Sesay; Anthony W Gebhard; Karamveer Birthare; James R Olson; Kate Rittenhouse-Olson
Journal:  Neoplasia       Date:  2017-08-19       Impact factor: 5.715

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.